160 related articles for article (PubMed ID: 34197279)
1. Next generation sequencing in therapy-related myeloid neoplasms compared to
Claerhout H; Vranckx H; Lierman E; Michaux L; Boeckx N
Acta Clin Belg; 2022 Jun; 77(3):658-663. PubMed ID: 34197279
[TBL] [Abstract][Full Text] [Related]
2. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
3. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
5. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.
Nardi V; Winkfield KM; Ok CY; Niemierko A; Kluk MJ; Attar EC; Garcia-Manero G; Wang SA; Hasserjian RP
J Clin Oncol; 2012 Jul; 30(19):2340-7. PubMed ID: 22585703
[TBL] [Abstract][Full Text] [Related]
7. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.
Ronaghy A; Hu S; Tang Z; Wang W; Tang G; Loghavi S; Li S; Thakral B; Medeiros LJ; Muzzafar T
Mod Pathol; 2021 Feb; 34(2):300-313. PubMed ID: 33110238
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
9. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.
Shah MV; Mangaonkar AA; Begna KH; Alkhateeb HB; Greipp P; Nanaa A; Elliott MA; Hogan WJ; Litzow MR; McCullough K; Tefferi A; Gangat N; Patnaik MM; Al-Kali A; He R; Chen D
Blood Cancer J; 2022 Jul; 12(7):106. PubMed ID: 35803921
[TBL] [Abstract][Full Text] [Related]
11. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
12. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
Higgins A; Shah MV
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640569
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
[TBL] [Abstract][Full Text] [Related]
16. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
17. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.
Hogg G; Severson EA; Cai L; Hoffmann HM; Holden KA; Fitzgerald K; Kenyon A; Zeng Q; Mooney M; Gardner S; Chen W; Nagan N; Boles D; Parker S; Richman TJ; Letovsky S; Dong H; Anderson SM; Ramkissoon S; Reddy P; Eisenberg M; Chenn A; Jensen TJ
Cancer Genet; 2023 Nov; 278-279():38-49. PubMed ID: 37586297
[TBL] [Abstract][Full Text] [Related]
18. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
19. The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.
Fabiani E; Fianchi L; Falconi G; Boncompagni R; Criscuolo M; Guidi F; La Brocca A; Hohaus S; Leone G; Voso MT
Leuk Lymphoma; 2014 Jul; 55(7):1538-43. PubMed ID: 24047476
[TBL] [Abstract][Full Text] [Related]
20. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
